Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Renal Cell Carcinoma
What perioperative systemic therapy would you use for a patient with oligometastatic clear cell RCC with a bony metastasis at risk for fracture?
Related Questions
How do you manage anemia associated with belzutifan therapy?
Do you routinely continue patients on anti-PD(L)-1 beyond 2 years of treatment while on IO/TKI for metastatic ccRCC?
With increasing overlap between advanced clear cell and non-clear cell RCC management with IO+TKI therapy, are there subtypes of non-clear cell RCC for which you would not use this approach?
How do you manage hypoxia induced by belzutifan?
What is your approach to surveillance in patients with no evidence of disease after treatment of oligometastatic renal cell carcinoma?
How do you reconcile the lack of OS benefit in the CLEAR trial comparing Lenvatinib + Pembrolizumab to Sunitinib, to the very impressive ORR and mPFS benefit seen?
What is your preferred approach to low volume unresectable/metastatic favorable risk RCC?
Would you offer adjuvant immunotherapy (pembrolizumab) for chromophobe RCC with R1 resection?
Is there still a role for mTOR inhibitors in metastatic RCC in the immunotherapy/TKI era?
What adjuvant therapy, if any, is best for mucinous tubular and spindle cell carcinoma of the kidney?
